<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR100">
 <label>100.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Arabi</surname>
    <given-names>YM</given-names>
   </name>
   <name>
    <surname>Asiri</surname>
    <given-names>AY</given-names>
   </name>
   <name>
    <surname>Assiri</surname>
    <given-names>AM</given-names>
   </name>
   <name>
    <surname>Jokhdar</surname>
    <given-names>HAA</given-names>
   </name>
   <name>
    <surname>Alothman</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Balkhy</surname>
    <given-names>HH</given-names>
   </name>
   <name>
    <surname>AlJohani</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Al Harbi</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Kojan</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Al Jeraisy</surname>
    <given-names>M</given-names>
   </name>
  </person-group>
  <article-title>Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-Î²1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial</article-title>
  <source>Trials</source>
  <year>2020</year>
  <volume>21</volume>
  <issue>1</issue>
  <fpage>1</fpage>
  <lpage>8</lpage>
  <pub-id pub-id-type="pmid">31898511</pub-id>
 </element-citation>
</ref>
